Trial · NCT02311998
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Bosutinib All Phase I Participants | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 1 | 400 | Milligrams | ||
| Number of Participants With a Major Hematologic Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 1 | 3 | Participants | ||
| Number of Participants With a Major Hematologic Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 2 | 4 | Participants | ||
| Number of Participants With a Major Hematologic Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 3 | 8 | Participants | ||
| Number of Participants With a Major Hematologic Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase II | 4 | Participants | ||
| Duration of Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 1 | 4.1 | Full Range 1.9 to 8.8 | Months | |
| Duration of Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 2 | 7.7 | Full Range 6.2 to 73.8 | Months | |
| Duration of Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 3 | 27.2 | Full Range 2.1 to 68.9 | Months | |
| Duration of Response | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase II | 5.1 | Full Range 0.7 to 8.1 | Months | |
| Overall Survival (OS) | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 1 | 8.2 | Full Range 6.8 to 10.7 | Months | |
| Overall Survival (OS) | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 2 | 9.6 | Full Range 2.0 to 74.6 | Months | |
| Overall Survival (OS) | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 3 | 47.5 | Full Range 2.7 to 72.8 | Months | |
| Overall Survival (OS) | Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase II | 5.3 | Full Range 2.0 to 28.2 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02311998/results